These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 29368256)

  • 21. Immune Therapies in Multiple Myeloma.
    Kumar SK; Anderson KC
    Clin Cancer Res; 2016 Nov; 22(22):5453-5460. PubMed ID: 28151713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD38 as an immunotherapeutic target in multiple myeloma.
    Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
    Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.
    Guillerey C; Nakamura K; Vuckovic S; Hill GR; Smyth MJ
    Cell Mol Life Sci; 2016 Apr; 73(8):1569-89. PubMed ID: 26801219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy for multiple myeloma.
    Rosenblatt J; Bar-Natan M; Munshi NC; Avigan DE
    Expert Rev Hematol; 2014 Feb; 7(1):91-6. PubMed ID: 24417573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in multiple myeloma--possibility or probability?
    Harrison SJ; Cook G
    Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma.
    Nguyen-Pham TN; Jung SH; Vo MC; Thanh-Tran HT; Lee YK; Lee HJ; Choi NR; Hoang MD; Kim HJ; Lee JJ
    J Immunother; 2015 Oct; 38(8):330-9. PubMed ID: 26325377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.
    D'Souza C; Prince HM; Neeson PJ
    Front Immunol; 2021; 12():632399. PubMed ID: 33746969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Immune Therapies for Myeloma.
    Rosenblatt J; Avigan D
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1440-7. PubMed ID: 26553769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy of multiple myeloma: the start of a long and tortuous journey.
    Harrison SJ; Cook G; Nibbs RJ; Prince HM
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1769-85. PubMed ID: 17181491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.
    Castella M; Fernández de Larrea C; Martín-Antonio B
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30445802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities.
    Liu P; Jin Y; Sattar H; Liu H; Xie W; Zhou F
    J Leukoc Biol; 2018 May; 103(5):821-828. PubMed ID: 29733502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging immunotherapies in multiple myeloma.
    Shah UA; Mailankody S
    BMJ; 2020 Sep; 370():m3176. PubMed ID: 32958461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Immunotherapies for Multiple Myeloma.
    D'Agostino M; Boccadoro M; Smith EL
    Curr Hematol Malig Rep; 2017 Aug; 12(4):344-357. PubMed ID: 28819882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.
    Dosani T; Carlsten M; Maric I; Landgren O
    Blood Cancer J; 2015 Apr; 5(4):e306. PubMed ID: 25885426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
    Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.